Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.

Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, Tyrone J, VandeVrede L, Willis D, Hansson O, Khachaturian AS, Schindler SE, Weiss J, Batrla R, Bozeat S, Dwyer JR, Holzapfel D, Jones DR, Murray JF, Partrick KA, Scholler E, Vradenburg G, Young D, Braunstein JB, Burnham SC, de Oliveira FF, Hu YH, Mattke S, Merali Z, Monane M, Sabbagh MN, Shobin E, Weiner MW, Udeh-Momoh CT.